Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis

Company Overview

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience. Its pipeline has included internally discovered and developed drug candidates, as well as programs advanced through collaborations and strategic partnerships. The company’s approach combines laboratory experimentation with computational tools to support target discovery, compound design, preclinical testing and clinical development.

Founded in 2013 and headquartered in Salt Lake City, Utah, Recursion operates as an international biotechnology organization through its research activities, partnerships and collaborations. In 2024, Recursion completed a combination with Exscientia plc, a United Kingdom-based company specializing in artificial intelligence-driven drug design, expanding Recursion’s capabilities in computational chemistry and medicine discovery. Recursion was co-founded by Chris Gibson, who serves as chief executive officer.

Key Stats

• Today's Range: $4.23 to $4.60
• 50-Day Range: $2.97 to $4.78
• 52-Week Range: $2.77 to $7.18
• Volume: 40.58 million shs
• Average Volume: 19.03 million shs
• Market Capitalization: $2.29 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.06
• Consensus Rating: Hold

Recursion Pharmaceuticals Stock Analysis - MarketRank™

Recursion Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat, and ranked 645th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Recursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Recursion Pharmaceuticals has a consensus price target of $8.06, representing about 85.5% upside from its current price of $4.35.

Amount of Analyst Coverage

Recursion Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Recursion Pharmaceuticals are expected to remain at ($0.94) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Recursion Pharmaceuticals is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Recursion Pharmaceuticals is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Recursion Pharmaceuticals has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

35.76% of the float of Recursion Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Recursion Pharmaceuticals has a short interest ratio ("days to cover") of 12.56, which indicates bearish sentiment.

Change versus previous month

Short interest in Recursion Pharmaceuticals has recently decreased by 0.24%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Recursion Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Recursion Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.24

News Sentiment

Recursion Pharmaceuticals has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Recursion Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

41 people have searched for RXRX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.

MarketBeat Follows

30 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 131% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Recursion Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $434,976.00 in company stock.

Percentage Held by Insiders

6.65% of the stock of Recursion Pharmaceuticals is held by insiders.

Percentage Held by Institutions

89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/07/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RXRX
• CIK: 1601830
• Web: www.recursion.com
• Phone: 385-269-0203
• Fax: 801-821-2872
• Employees: 600
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Recursion Pharmaceuticals: $8.06
• High Price Target: $11.00
• Low Price Target: $5.30
• Potential Upside/Downside: +88.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$644.76 million
• Net Margins: -945.94%
• Pretax Margin: -954.29%
• Return on Equity: -50.41%
• Return on Assets: -38.25%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.03
• Quick Ratio: 5.03

Sales & Book Value

• Annual Sales: $74.68 million
• Price / Sales: 30.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.14 per share
• Price / Book: 2.00

Miscellaneous

• Outstanding Shares: 535,340,000
• Free Float: 499,742,000
• Market Cap: $2.29 billion
• Optionable: Optionable
• Beta: 1.04